It's two sites but still the Arizona Cancer Center.
I think two more Cancer Centers will be announced. I hope for M.D. Anderson in Houston and somewhere in the NYC area. I also expect a few parallel experiments at the Bethesda NCI campus. BTW, this is not the standard 'kill the cancer before we kill the patient' trial, if efficacy is shown then John Q. Public will hear about it. "Patients who demonstrate an objective response to therapy may be offered continued treatment on an extension protocol.
For the viral trial I would look for the sites to be anywhere other HCV trials have been run. There may be only one site, 32 patients should not be hard to recruit for a disease affecting 170 million people (worldwide) in which the standard treatment fails 50% of the time. The early data should equate to the same for HPV, HIV, Avian and other influenzas. That's when 'Tarvacin Anyone?' is launched. Also - and never to be underestimated - we still have a good shot at hearing something about Tarvacin for the hemorrhagic viruses. I'm talking Bio-Shield bucks here, generally gov't contracts are cost + 5% but it's a very big number - an anthrax maybe vaccine was recently awarded $800,000,000.
On the preliminary list for being booted from the Russell 2000/3000 and being picked up by the Russell microcap. I think it is stupid to assume the 12,000,000 shares Barclays holds are all index related. We shall see if PPHM is still on the boot list June 24, very interesting twelve days coming up.
News 
Market Data 
Discover 
AI
